RBC Capital analyst Shagun Singh initiated coverage of Insulet (PODD) with an Outperform rating and $340 price target The firm says Insulet has a “differentiated” technology offering with the only available patch automated insulin delivery system on the market and competitive advantages. Key opinion leader checks suggest upside to consensus/ estimates, driven by global Omnipod 5, the analyst tells investors in a research note. Further, RBC sees at least 100 basis points of annual margin expansion, driving 26% annual earnings growth over Insulet’s next three years and the stock higher.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet’s Strategic Expansion and Competitive Edge Drive Buy Rating
- Wells Fargo downgrades Tandem Diabetes on market share loss
- Insulet’s Promising Growth: Buy Rating Backed by Type 2 Diabetes Product Launch and AID System Advancements
- Insulet participates in a conference call with JPMorgan
- Insulet price target raised to $335 from $315 at Bernstein